Clinical Trial Update: Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study assessing enadenotucirev as a radiosensitiser with chemoradiation for locally advanced rectal cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Enadenotucirev (enadenotucirev)

Snippet

Sponsor: University of Oxford | Conditions: Locally Advanced Rectal Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-02-06